AstraZeneca’s new blood thinner Brilinta worked better than Plavix in a head-to-head clinical trial — but not in U.S. and Canadian patients. The FDA won’t approve the drug without a new analysis of the study.
More here:
FDA Rejects New Blood Thinner — for Now